Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01379040 · ClinicalTrials.gov registry record
Volatile Organic Compounds in Cystic Fibrosis
A clinical trial, sponsored by Landon Pediatric Foundation.
- Completed
- Registry status
- 24
- Enrollment target
NCT01379040: Completed study, sponsored by Landon Pediatric Foundation.
NCT01379040 is a clinical trial that has completed, run by Landon Pediatric Foundation. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01379040 has completed, sponsored by Landon Pediatric Foundation.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial organisms in the lower respiratory tract. It consists of: * A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air. * Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography. * Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection. This study will test the hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling the "head space" above culture media of sputum provided by patients with cystic fibrosis. This study will test the additional hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling exhaled breath from the patient providing the sputum.
Primary Outcome
Patient's provided breath samples and sputum for culture. Bacterial identification by indices was achieved
Interventions
- OTHER Cystic Fibrosis patients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-12 |
What the finished NCT01379040 record still lists
NCT01379040 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cystic Fibrosis patients is the first listed.
NCT01379040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01379040 about?
NCT01379040 is a clinical study titled "Volatile Organic Compounds in Cystic Fibrosis". This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial organisms in the lower respiratory tract. It consists of: * A breath collec...
What is the current status of trial NCT01379040?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2009-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01379040?
The interventions under investigation include: Cystic Fibrosis patients (OTHER).
Who is sponsoring clinical trial NCT01379040?
This trial is sponsored by Landon Pediatric Foundation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia